.jpg)
Driving Global Healthcare Innovation Across Diagnostics and Therapeutics
Founded in 1999 with a unified corporate vision to build a healthier world through translational science, YashrajBiotechnology Ltd. (YBL) has evolved from a pioneering indigenous manufacturer of native biomarkers into aninternationally recognized leader in In Vitro Diagnostics (IVD) raw materials and advanced Preclinical IntegratedDrug Discovery (IDD) solutions. Headquartered in Navi Mumbai, India, and supported by established internationalsubsidiaries in Germany and the USA, YBL operates at the vital intersection of deep biomedical research and highlyscalable contract manufacturing.
For over two decades, our core mission has been to provide the global scientific and medical community withuncompromised access to premium biological reagents and cutting-edge screening platforms. We serve a diverse,elite global clientele—spanning multinational diagnostic kit manufacturers, premier pharmaceutical companies,and innovative biotech startups—helping them accelerate their R&D timelines, reduce regulatory friction, andbring life-saving diagnostic assays and therapeutic candidates to market faster.
Our Vision
Be the Key Player in Life Sciences – Diagnostics and Drive Innovation for Making a Healthier World
In 1999, a shared passion for science and research brought three thorough-bred professionals together; Mr. Arvind Bhanushali, Mr. Bharat Dagha and Dr. Paresh Bhanushali who joined hands together and laid the foundation with a few dedicated team members. While the beginning was humble, the passion was immense and the intent was to set a new benchmark in the in vitro diagnostic (IVD) segment and make an impact in the global space
.svg)
Our Belief Systems for Effective Decision Making and Optimal Functioning
Commitment
We always honor our given commitments to the utmost by not over-promising
Consistency
We will be consistently consistent in delivering products and services
Innovation
We strive for excellence by constantly innovating our products, services and processes and thereby live our motto - A bio-quest forever
Fairness
We create opportunities for our customers, employees & community to speak their mind and have their ideas, opinions and feelings heard, and offer them fair solutions - so that all may win
Responsible Business
We will always do what is right. Profit-centered conflicts will never get in the way of doing what is right. We will always follow all the laws of the land in spirit and set the highest standards for our products/services, thereby contributing towards making a healthier world
Since 1999, we have been innovating in the diagnostics space to make a healthier world. From being a Native Antigen manufacturer, we have substantially enhanced our portfolio over the years to become a premium provider of IVD raw materials and pre-clinical drug discovery services. Our relentless passion to make a healthier world drives us to continually focus on the emerging unmet needs in the diagnostics space and become the preferred partner to our customers
Get In Touch
Our Technical Ecosystem and Operational Framework
1. Tightly Regulated,Healthcare-Direct SourcingMatrix
The foundation of our scientific consistency begins at the pointof collection. YBL operates aclosed-loop biological procurement infrastructure encompassing a vast, ethically managed network of over1,500 partner hospitals andclinical facilities. This direct access allows our logistics teams to enforce rigid,validated cold-chain protocol simmediately upon fluid collection. By eliminating third-party brokers, we secure complete patient-cohortcharacterization, minimizede mographic variables, and preserve the native structuralintegrity of biological specimens before they everenter our processing laboratories.
2. Advanced Bioprocess Development and Manufacturing Scale-Up2. Translationally Relevant Preclinical Integrated Drug Discovery (IDD)
Our operational strength lies inour ability to translate complex laboratory protocols intoindustrial-scale production. Operating out of state-of-the-art, DSIR-approved R&Dlaboratories, our technical teams specialize in large-volume upstream processing aswell as down stream purification workflows. Whether we are purifying delicate native proteins fromclinical matrices or engineeringcustom recombinant expression vectors in bacterialor mammalian cell lines, ourfacilities are optimized todeliver high-yield extractions while maintaining strict structural and conformationa lfidelity laboratories.
3. A 25-Year Legacy of Technical Expertise and Technological Evolution
Our deepest asset is a quarter-centuryof specialized experience intranslational science. YBL has spent 25years mastering the intricacies ofprotein biochemistry, immunochemical interactions, andbulk manufacturing for the global InVitro Diagnostics (IVD) industry. This foundational expertise has recentlybeen channeled into a bold expansioninto cutting-edge cellular technologies.
By blending our extensive knowledge of clinical biomarkers with state-of-the-art stem cell engineering, we nowdevelop advanced, human-relevant induced pluripotent stem cells (iPSCs)and complex in vitro models. This powerful intersection of legacy and innovation allows us to deliver next-generation screening platforms thatmirror human physiology with exceptional accuracy—ultimately accelerating preclinical drugdevelopment pipelines and shaping the future of global bio medical research, processing laboratories.
With a clear vision and strong values, YBL has grown from strength to strength scaling from one milestone to another transcending over the last 23 years. Today YBL is a trusted partner to the top IVD companies globally and is well poised to supply Diagnostic Reagents for the development of kits, calibrators, and immunogen grade proteins
Get In Touch
YBl - A legacy of commitment and Growth
With a clear vision and strong values, YBL has grown from strength to strength scaling from one milestone to another transcending over the last 23 years. Today YBL is a trusted partner to the top IVD companies globally and is well poised to supply diagnostic reagents for the development of kits, calibrators, and immunogen grade proteins
1999
Company Incorporated
2000
Native antigen production and commercial operations
2007
Developed monoclonal antibodies
2012
Commercial Launch of Recombinant Antigens
2015
Subsidiary – Berlin, Germany
2017-18
Subsidiary - Delaware, USA
2019-20
R&D on recombinant mAbs using Antibody Phage Display (APD)
2020-21
Expanded into stem cell research using iPSC
2021-22
Goat Farm for polyclonal antibodies
2022-23
Commercial launch of stem cell derivatives
Commissioned production -scale bacterial fermentation facility
